The 7 most recent market catalysts affecting $DNTH, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 18, 2026
Corporate Catalyst
Neutral
Impact 65
Dianthus Therapeutics Files Automatic Mixed Shelf Registration; Size Not Disclosed
An automatic mixed shelf registration allows a company to issue various types of securities (stocks, bonds, warrants) over a period without needing to file a new prospectus for eac…
Sep 11, 2026
Corporate Catalyst
Neutral
Impact 65
JP Morgan Initiates Coverage On Dianthus Therapeutics with Overweight Rating, Announces Price Target of $135
JP Morgan analyst Brian Cheng initiated coverage on Dianthus Therapeutics (DNTH) with an Overweight rating and a $135 price target. This is a significant event for DNTH as a major …
Sep 4, 2026
Corporate Catalyst
Neutral
Impact 75
Citigroup Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $156
Citigroup's initiation of coverage on Dianthus Therapeutics with a 'Buy' rating and a $156 price target is a strong vote of confidence from a major investment bank. This event is s…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on Dianthus Therapeutics, Raises Price Target to $128
Truist Securities analyst Danielle Brill maintained a 'Buy' rating on Dianthus Therapeutics (DNTH) and raised the price target from $110 to $128. This action signals continued conf…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Dianthus Therapeutics, Raises Price Target to $158
HC Wainwright & Co. analyst Swayampakula Ramakanth maintained a 'Buy' rating on Dianthus Therapeutics (DNTH) and raised the price target from $130 to $158. This analyst action sign…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 65
Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $122
Wedbush analyst Laura Chico maintained an 'Outperform' rating on Dianthus Therapeutics (DNTH) and raised the price target from $105 to $122. This action signals increased confidenc…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 92
Dianthus Therapeutics Q2 EPS $(0.90) Misses $(0.88) Estimate, Sales $761.000K Beat $258.583K Estimate
Dianthus Therapeutics' Q2 filing reveals a mixed financial performance. While the company's losses per share were slightly worse than anticipated, indicating higher operating costs…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.